InNexus Biotechnology Inc, a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology, has received a notice of allowance on patent claims in the United States (Serial No 11/119,404) and a patent grant in India (National Phase Application No 2424/CHENP/2005) further expanding its protection of InNexus' DXL technology.

Speaking during the announcement, InNexus chairman and CEO, Jeff Morhet said, "DXL antibodies that penetrate directly into cells, is an exciting achievement for InNexus and our industry. As we've continued to expand our patent portfolio and discover new technologies to develop products, the team has aggressively pursued patent protection for our novel inventions. Patents are the currency of our industry and a driver for enhanced value for our shareholders and potential use of these cell penetrating DXL antibodies represents another frontier for the use of antibodies for therapeutic and diagnostic applications."

Dr Thomas Kindt, chief scientific officer of InNexus said, "The claims in these patents are directed toward the addition of membrane transport sequences to DXL antibodies, which facilitate penetration of DXL antibodies into cancer cells. The ability to direct our DXL antibodies to intracellular targets by the addition of a membrane transport sequence, imparts great therapeutic potential in a number of applications. The patents and applications also include coverage for new molecules and products of InNexus. We like to say we build better antibodies and we have demonstrated that once again".

InNexus also announced that Jeff Morhet, chairman and CEO, was recently highlighted and quoted in an article titled 'JAMA study casts cloud over biologic safety' in the January 2009 issue of Nature Biotechnology. Nature Biotechnology is a widely read academic journal published by Nature Publishing Group, a division of Macmillan Publishers Ltd, covering the science and business of biotechnology.

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.